Search academic texts

Information × Registration Number 0215U003242, 0112U004849 , R & D reports Title To optimize the treatment of relapsed and refractory malignant lymphoma and multiple myeloma patients (multicenter study). popup.stage_title Head Kryachok Iryna, Registration Date 22-01-2015 Organization Ukrainian Research Institute of Oncology and Radiology popup.description2 Object of study - refractory and relapsed forms of Hodgkin's lymphoma , non-Hodgkin lymphoma and multiple myeloma patients, immunohistochemistry and molecular- genetic factors of the disease. Aim of study - To develop and optimize programs of differentiated treatment for refractory and relapsed forms of Hodgkin's lymphoma , non-Hodgkin lymphoma , multiple myeloma using new chemotherapy regimensand stem cell transplantation, detection of clinical hematological, immunophenotypic and molecular genetic prognosis criteria . Methods and apparatus: morphological, immunohistochemical, clinical, statistical, ultrasound system "Aloca", CT. 180 patients with refractory and relapsed forms of non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (LH and 93 patients with multiple myeloma were included in a study group . Retrospective group (control ) consisted of 90 patients with refractory and relapsedforms of non-Hodgkin's lymphoma, Hodgkin's lymphoma . To determine prognosis markers of the disease 534 studies were conducted. In patients with LH were determined expression levelof Ki- 67 antigen, expression of EBV in tumor cells, polymorphism of GSTP1 gene, expression level of PD- 1 ligands . In patients with NHL determined expression level of markers Ki -67, P -53 , Bcl-2 , Pgp, PKCb, polymorphism of GSTP1gene, expression level of PD- 1 ligands . In patients with multiple myeloma was performed molecular genetic analysis for detection of del 13q, del 17p, t ( 4; 14 ), t ( 14; 16). Relapsed and primary refractory forms of LH and the NHL treated by second line therapy is highly effective, immediate effectiveness of therapy using regimens based on cisplatin was 52.1 % and 74.8 % , based on gemcitabine - 55.5 % and 57.14 %, respectively (p> 0.005) . 3-year overall survival of patients with refractory and relapsed forms of LH and NHL was 88 % and 47 %, respectively.It is proved that the most effective approach to the treatment of refractory and relapsed forms of lymphoma are chemotherapy regimens based on cisplatin compared with gemcitabine . It was established that high level expression of protein Ki - 67, the presence of EBV, high level expression of PD-L1 and genotype Val / Val gene GSTP1 are negative prognostic markers for Hodgkin's lymphoma. The genotype of GSTP1 gene A313A , high level expression of PD-L1, the presence of the expression of bcl-2 , Ki- 67, p -53 , pgp, RKS?II in tumor cells are negative prognostic markers and predictors for non-Hodgkin lymphomas. Therapy with thalidomide demonstrated high efficacy in patients with multiple myeloma (total efficiency was 78.8 %). Field of implementation - oncology. Product Description popup.authors Мартинчик А.В. Новосад О.І. Титоренко І.Б. Яценко Л.Д. popup.nrat_date 2020-04-02 Close